HT
OREX

HAP Trading’s Orexigen Therapeutics, Inc. OREX Stock Holding History

HAP Trading’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,068
Closed -$255K – 1283
2015
Q3 		$255K Buy
+12,068
New +$414K 0.01% 480

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HAP Trading's OREX Position: Q4 2015 in Review

HAP Trading sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 12,068 shares — an estimated $255K sold.

HAP Trading first reported a position in OREX in Q3 2015 and held it in 1 quarter. The position peaked at $255K in Q3 2015. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

  • HAP Trading reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • HAP Trading sold 12,068 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $255K.
  • HAP Trading first reported a position in Orexigen Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • HAP Trading's Orexigen Therapeutics, Inc. position peaked at $255K in Q3 2015.
  • 121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on HAP Trading's 13F filing for Q4 2015, filed 12 Feb 2016.